TransMedics Group, Inc. (TMDX) reported third-quarter 2024 earnings per share (EPS) of 12 cents, which missed the Zacks Consensus Estimate of 28 cents by 57.1%. The company recorded a loss per share of 78 cents in the year-ago period. TransMedics registered revenues of $108.8 million, up 63.9% year over year. The figure, however, missed the Zacks Consensus Estimate by 4.8%. The year-over-year increase in sales was driven by the increase in utilization of the Organ Care System (OCS) across all three organs a ...

TransMedics Group (NASDAQ: TMDX ) shares are falling about 25% in pre-market hours after an extremely disappointing third-quarter report, which showed Wall Street, and I, got way ahead of ourselves.I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfo ...

TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday. TransMedics reported quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 30 cents per share. The company reported quarterly sales of $108.76 million which missed the analyst consensus estimate of $115.00 million. "We are proud of our performance year to date and look forward to ending 2024 on a strong note," said Waleed Hassanein, president and CEO of TransMedics. "We continued to make meaningful pr ...

Is this the buy-the-dip opportunity investors have been waiting for? In this video, I will be going over TransMedics Group's (TMDX 0.85%) third-quarter earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock prices used were from the trading day of Oct. 29, 2024. The video was published on Oct. 29, 2024. ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX) complied with federal securities laws. The Firm's investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors. Investors who purchased TransMedics securities and those with information about t ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $108.8 million, representing a 64% increase from Q3 2023, but a 5% decline sequentially from Q2 2024 [14][32] - US sales increased by 76% year-over-year but declined by 3% sequentially, while OUS sales saw a 40% year-over-year decline and a 45% sequential decline [14][33] - Gross margins for Q3 were 56%, down from 61% in Q2 2024, attributed to ongoing investments in logistics and clinical resources [16][36] - GAAP operating profit was $3.9 million, or 4% of total revenue, compared to an operating loss of $28.3 million in Q3 2023 [43] Business Line Data and Key Metrics Changes - TransMedics transplant logistics service revenue for Q3 was $20.1 million, up from $2.1 million in Q3 2023 and up from $19.1 million in Q2 2024 [15] - US organ revenue breakdown included $76.7 million in liver, $24.5 million in heart, and $3.7 million in lung [33] - OUS revenue was $2.6 million, with $2.4 million in heart and $0.2 million in lung, reflecting a small portion of the business [33] Market Data and Key Metrics Changes - Overall US national liver and heart transplant volumes declined sequentially by approximately 5%, while total lung volumes declined by approximately 3% [20] - The decline in case volume was attributed to normal variability in donor availability and potential summer seasonality, with no degradation in market share reported [21][22] Company Strategy and Development Direction - The company is focused on building its transplant logistics network and aviation infrastructure, investing in clinical and technology infrastructures, and developing next-gen OCS Heart and Lung technologies for clinical programs in 2025 [10][11][12] - The company aims to catalyze growth in the OCS Lung market and expand OCS Heart adoption, with a goal of achieving 10,000 transplants by 2028 [66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth despite Q3 challenges, maintaining annual revenue guidance of $425 million to $445 million, representing 76% to 84% growth over 2023 [31][46] - Management noted that the decline in transplant volumes was a transient event and expected recovery in Q4 [66][80] Other Important Information - The company has expanded its fleet of owned aircraft to 18 and is investing in internal aircraft maintenance infrastructure to enhance operational efficiency [17][18] - Total cash at the end of Q3 was $330.1 million, a decrease of $32.7 million from June 30, 2024, with $7 million generated in operating cash during the quarter [43][44] Q&A Session Summary Question: Dynamics in Q4 and guidance confidence - Management noted that early October showed signs of normalization, supporting their guidance reiteration [51] Question: Breakdown of organ performance - Management clarified that the decline in heart transplant volumes was not due to competitive dynamics but rather a national volume decline [53] Question: Service margin expectations - Management indicated that nonrecurring expenses would not repeat in Q4, and efficiency improvements are expected as more owned planes are utilized [57][59] Question: Share stabilization and future expectations - Management expects to maintain share exiting Q3 and aims for better performance in Q4 [88] Question: Impact of maintenance on aircraft capacity - Management explained that they plan for maintenance and operational efficiency to minimize future impacts on logistics [88][89] Question: New OCS versions and their integration - Management discussed the introduction of next-generation OCS technologies aimed at improving transplant outcomes and expanding clinical programs [91]

TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -57.14%. A quarter ago, it was expected that this medical technology company would post earnings of $0.21 per share when it actually produced earnings of $0.35, delivering a surprise of 66.67%.Over the last four quarters, ...

Exhibit 99.1 TransMedics Reports Third Quarter 2024 Financial Results Andover, Mass. – October 28, 2024 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights ▪ Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023 ▪ Gen ...

ANDOVER, Mass., Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024. Recent Highlights Total revenue of $108.8 million in the third quarter of 2024, a 64% increase compared to the third quarter of 2023 Generated net income of $4.2 million or $0.12 per diluted share in ...

Analysts on Wall Street project that TransMedics (TMDX) will announce quarterly earnings of $0.28 per share in its forthcoming report, representing an increase of 333.3% year over year. Revenues are projected to reach $114.22 million, increasing 71.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a co ...